FDA use of advisory committees not optimum

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1570, 2007-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lindane: FDA issues public health advisory

By  

Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

New US advisory endorses statin use

By  

Inpharma, Vol. 1, Iss. 1347, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

A US FDA advisory committee recommends that alosetron [`Lotronex'; GlaxoSmithKline] be reintroduced

By  

Inpharma, Vol. 1, Iss. 1336, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

FDA propose drug label changes for use in pregnancy

By  

Reactions Weekly, Vol. 1, Iss. 1205, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Coverage Policy and Use Beyond the FDA-Approved Label

By McGivney William T.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 2, 2006-02 ,pp. : 99-101

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite